frankforwin,
The company missed its primary endpoint (50 day), and that doesn't usually go over too well with the FDA. However, they barely missed...and other endpoints like 80 days were spectacular. Very much like DNDN, if you follow Dendreon and their drug Provenge. Risk/reward is extremely commpelling for DORB, IMHO. I am long quite a bit of shares.
Best regards,
Geoff
Market Data 
Markets 
AI
